Key result
Pulmonary hypertension is characterized by increased pulmonary vascular resistance and right ventricular hypertrophy, with current therapies limited to supportive care and targeting vasoconstriction.
This review provides a succinct overview of the clinical classification and pathophysiology of pulmonary hypertension.
Underscores unmet need for disease-modifying therapies; leaves open mechanistic research into vascular remodeling and RV protection.
Pulmonary hypertension is a fatal disease of multiple etiologies that is estimated to affect over 100 million people worldwide. The disease is defined hemodynamically as a mean pulmonary artery pressure ≥ 25 mmHg at rest. Despite important advances in our understanding of the pathobiology of this disease and improvements in patient management, outcomes are still poor and no curative treatments are currently available. The complex nature of this disease requires detailed clinical evaluation for accurate diagnosis and treatment. Recent advances in clinical recognition, classification, and understanding of the underlying pathological processes in pulmonary hypertension have led to improved diagnostic testing and therapeutic options for patients. A hallmark of pulmonary hypertension is an increased pulmonary vascular resistance which leads to progressive elevations in pulmonary artery pressure, resulting in compensatory right ventricular hypertrophy and, ultimately, heart failure. Clinically, these pulmonary vascular changes initially present as nonspecific symptoms, including unexplained dyspnea on exertion, fatigue, chest pain, and syncope. Signs of right ventricular dysfunction are also frequently present. Common pathogenic features of pulmonary hypertension include sustained pulmonary vasoconstriction, vascular remodeling of the small pulmonary arteries, in situ thrombosis, and increased vascular wall stiffness, resulting in increased pulmonary arterial pressure due to increased pulmonary vascular resistance. Despite improvements in clinical classification and understanding of the underlying pathogenic mechanisms of pulmonary hypertension, current therapies are limited to supportive care and targeting pulmonary vasoconstriction. There remains a need to identify novel therapeutic targets in this disease. This review provides a succinct overview of the clinical classification and pathophysiology of PH that can be used as a reference by physicians and physician‐scientists.
No takes yet. Share an insight, caveat, or question.
Sysol et al. (2018) conducted a review in Pulmonary hypertension. Pulmonary hypertension is characterized by increased pulmonary vascular resistance and right ventricular hypertrophy, with current therapies limited to supportive care and targeting vasoconstriction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: